98 related articles for article (PubMed ID: 9152398)
1. Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.
Shannon HE; Sheardown MJ; Bymaster FP; Calligaro DO; Delapp NW; Gidda J; Mitch CH; Sawyer BD; Stengel PW; Ward JS; Wong DT; Olesen PH; Suzdak PD; Sauerberg P; Swedberg MD
J Pharmacol Exp Ther; 1997 May; 281(2):884-94. PubMed ID: 9152398
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.
Shannon HE; Womer DE; Bymaster FP; Calligaro DO; DeLapp NC; Mitch CH; Ward JS; Whitesitt CA; Swedberg MD; Sheardown MJ; Fink-Jensen A; Olesen PH; Rimvall K; Sauerberg P
Life Sci; 1997; 60(13-14):969-76. PubMed ID: 9121363
[TBL] [Abstract][Full Text] [Related]
3. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
[TBL] [Abstract][Full Text] [Related]
4. Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic.
Swedberg MD; Sheardown MJ; Sauerberg P; Olesen PH; Suzdak PD; Hansen KT; Bymaster FP; Ward JS; Mitch CH; Calligaro DO; Delapp NW; Shannon HE
J Pharmacol Exp Ther; 1997 May; 281(2):876-83. PubMed ID: 9152397
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M.
Dallanoce C; Conti P; De Amici M; De Micheli C; Barocelli E; Chiavarini M; Ballabeni V; Bertoni S; Impicciatore M
Bioorg Med Chem; 1999 Aug; 7(8):1539-47. PubMed ID: 10482446
[TBL] [Abstract][Full Text] [Related]
6. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
Sauerberg P; Olesen PH; Nielsen S; Treppendahl S; Sheardown MJ; Honoré T; Mitch CH; Ward JS; Pike AJ; Bymaster FP
J Med Chem; 1992 Jun; 35(12):2274-83. PubMed ID: 1613751
[TBL] [Abstract][Full Text] [Related]
7. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
Sheardown MJ; Shannon HE; Swedberg MD; Suzdak PD; Bymaster FP; Olesen PH; Mitch CH; Ward JS; Sauerberg P
J Pharmacol Exp Ther; 1997 May; 281(2):868-75. PubMed ID: 9152396
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of a novel, potent and selective M3 antagonist.
Ghelardini C; Bartolini A; Galeotti N; Bellucci C; Dei S; Gualtieri F
Life Sci; 1997; 61(13):1217-26. PubMed ID: 9324063
[TBL] [Abstract][Full Text] [Related]
9. New analogues of oxotremorine and oxotremorine-M: estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes.
Barocelli E; Ballabeni V; Bertoni S; Dallanoce C; De Amici M; De Micheli C; Impicciatore M
Life Sci; 2000 Jun; 67(6):717-23. PubMed ID: 12659177
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of tripitramine, a polymethylene tetraamine displaying high selectivity and affinity for muscarinic M2 receptors.
Chiarini A; Budriesi R; Bolognesi ML; Minarini A; Melchiorre C
Br J Pharmacol; 1995 Apr; 114(7):1507-17. PubMed ID: 7606355
[TBL] [Abstract][Full Text] [Related]
11. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
Bymaster FP; Wong DT; Mitch CH; Ward JS; Calligaro DO; Schoepp DD; Shannon HE; Sheardown MJ; Olesen PH; Suzdak PD; Swedberg MD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):282-9. PubMed ID: 7909558
[TBL] [Abstract][Full Text] [Related]
12. Central muscarinic inhibition of lower urinary tract nociception.
Thor KB; Muhlhauser MA; Sauerberg P; Shannon H; Springer JP
Brain Res; 2000 Jul; 870(1-2):126-34. PubMed ID: 10869509
[TBL] [Abstract][Full Text] [Related]
13. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .
Bymaster FP; Shannon HE; Rasmussen K; Delapp NW; Mitch CH; Ward JS; Calligaro DO; Ludvigsen TS; Sheardown MJ; Olesen PH; Swedberg MD; Sauerberg P; Fink-Jensen A
Eur J Pharmacol; 1998 Sep; 356(2-3):109-19. PubMed ID: 9774240
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
Hirose H; Aoki I; Kimura T; Fujikawa T; Numazawa T; Sasaki K; Sato A; Hasegawa T; Nishikibe M; Mitsuya M; Ohtake N; Mase T; Noguchi K
J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists.
Wallis RM
Life Sci; 1995; 56(11-12):861-8. PubMed ID: 10188786
[TBL] [Abstract][Full Text] [Related]
16. Distinct functional muscarinic receptors in guinea-pig gallbladder, ileum and atria.
Karaalp A; Akici A; Akbulut H; Ulusoy NB; Oktay S
Pharmacol Res; 1999 May; 39(5):389-95. PubMed ID: 10328997
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
Roffel AF; Davids JH; Elzinga CR; Wolf D; Zaagsma J; Kilbinger H
Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
[TBL] [Abstract][Full Text] [Related]
18. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs.
Noronha-Blob L; Kachur JF
J Pharmacol Exp Ther; 1991 Feb; 256(2):562-7. PubMed ID: 1993995
[TBL] [Abstract][Full Text] [Related]
19. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
[TBL] [Abstract][Full Text] [Related]
20. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
